Haemonetics Corporation HAE R2KR3KPHARMA
Company Overview
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Operating margin of 17.9% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $1.33B (-2.0% YoY); net profit $97.31M.
- Trailing 12 Months Year-on-year growth — revenue +5.6%, earnings +2.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.8%, profit CAGR 3.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.83% |
| 1 Year: | 5.60% |
Compounded Profit Growth
| 5 Years: | 2.96% |
| 1 Year: | 2.90% |
Stock Price Performance
| 1 Year: | +115.59% |
| 6 Months: | +94.83% |
| 3 Months: | +47.45% |
| 1 Month: | +8.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.60 · Neutral
P/E of 56.12 is above the sector median of 25.61 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 56.1.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HAE Haemonetics Corporation R2KR3KPHARMA | 116.16 | 56.12 | $5.28B | 0.00% | 7.42% | 11.20% | 4.83% | 2.96% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Apr 2016 | Jul 2016 | Oct 2016 | Dec 2016 | Apr 2017 | Jul 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Dec 2022 | Jul 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 210.95M | 225.38M | 234.04M | - | 229.35M | 241.58M | 247.36M | - | 238.45M | 252.57M | 258.97M | - | 195.58M | 209.49M | 240.37M | - | 228.53M | 239.90M | 259.77M | 261.46M | 297.49M | 305.30M | 311.33M | 318.18M | 336.25M | 336.17M | 345.51M | 348.54M | 321.39M | 327.31M | 338.97M | 339.38M |
| Gross Profit | 102.54M | 105.30M | 108.86M | 89.22M | 91.06M | 104.25M | 101.08M | 82.11M | 91.67M | 104.56M | 111.30M | 104.39M | 83.24M | 111.91M | 111.17M | 111.21M | 115.91M | 127.00M | 128.05M | 113.56M | 90.03M | 105.74M | 120.26M | 81.81M | 108.08M | 122.54M | 138.56M | 142.26M | 157.88M | 158.71M | 167.26M | 170.51M | 177.87M | 174.92M | 187.44M | 193.55M | 192.24M | 194.74M | 202.39M | 202.80M |
| Operating Income | 3.61M | 19.18M | -61.18M | -5.55M | -7.88M | 24.79M | 21.21M | -57.51M | 16.61M | 24.26M | 1.01M | 14.28M | 5.29M | 26.08M | 28.32M | 23.86M | -13.30M | 49.74M | 40.91M | 26.01M | 11.71M | 58.78M | 40.42M | -21.18M | 1.39M | 24.51M | 35.65M | 30.77M | 46.73M | 43.28M | 53.66M | 35.30M | 45.98M | 39.76M | 51.70M | 59.03M | 53.87M | 58.49M | 67.40M | 57.46M |
| Net Income | -267.00K | 12.86M | -59.44M | -8.73M | -10.35M | 19.82M | 15.39M | -51.14M | 20.14M | 20.10M | -6.55M | 11.88M | -2.82M | 18.73M | -8.48M | 20.84M | -8.48M | 37.49M | 29.89M | 17.62M | 10.53M | 48.10M | 31.88M | -11.04M | -4.45M | 14.86M | 23.23M | 19.88M | 33.20M | 32.94M | 41.04M | 24.91M | 31.24M | 38.37M | 33.83M | 37.49M | 34.03M | 38.68M | 44.74M | 33.01M |
| Diluted EPS | -0.01 | 0.25 | -1.17 | -0.17 | -0.20 | 0.38 | 0.30 | -0.98 | 0.38 | 0.38 | -0.12 | 0.22 | -0.05 | 0.35 | 0.35 | 0.40 | -0.17 | 0.72 | 0.58 | 0.34 | 0.21 | 0.94 | 0.62 | -0.22 | -0.09 | 0.29 | 0.45 | 0.38 | 0.64 | 0.64 | 0.80 | 0.48 | 0.61 | 0.74 | 0.66 | 0.74 | 0.70 | 0.81 | 0.95 | 0.72 |
| R&D Expense | 11.32M | 11.55M | 10.94M | - | 11.44M | 8.34M | 8.46M | - | 8.19M | 7.52M | 12.43M | - | 9.41M | 8.58M | 8.98M | - | 7.49M | 7.42M | 7.00M | - | 7.75M | 6.76M | 7.50M | - | 12.70M | 10.85M | 10.04M | 10.90M | 10.90M | 12.69M | 12.65M | 12.66M | 13.27M | 14.45M | 14.14M | 15.83M | 16.26M | 14.87M | 14.19M | 16.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2009 | Apr 2010 | Apr 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Apr 2016 | Apr 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 597.88M | 645.43M | 676.69M | 727.84M | 891.99M | 938.51M | 910.37M | 908.83M | 886.12M | 903.92M | 967.58M | 988.48M | 870.46M | 993.20M | 1.17B | 1.31B | 1.36B | 1.33B |
| Gross Profit | 308.17M | 337.48M | 355.21M | 369.24M | 428.13M | 468.37M | 434.42M | 405.91M | 378.49M | 411.91M | 417.54M | 484.51M | 397.84M | 505.50M | 615.10M | 691.55M | 748.96M | 787.59M |
| Operating Income | 85.57M | 83.28M | 110.55M | 88.76M | 56.44M | 46.43M | 40.54M | -43.94M | -19.38M | 56.16M | 83.55M | 103.35M | 89.75M | 80.75M | 156.03M | 164.88M | 221.82M | 156.73M |
| Net Income | 59.30M | 58.37M | 79.98M | 66.89M | 38.80M | 35.15M | 16.90M | -55.58M | -26.27M | 45.57M | 55.02M | 76.53M | 79.47M | 43.38M | 115.40M | 117.56M | 167.68M | 97.31M |
| Diluted EPS | 2.27 | 2.24 | 1.56 | 1.30 | 0.74 | 0.67 | 0.32 | -1.09 | -0.51 | 0.85 | 1.04 | 1.48 | 1.55 | 0.84 | 2.24 | 2.29 | 3.31 | 2.05 |
| R&D Expense | 23.86M | 26.38M | 32.66M | 36.80M | 44.39M | 54.20M | 54.19M | 44.97M | 37.56M | 39.23M | 35.71M | 30.88M | 32.86M | 46.80M | 50.13M | 54.44M | 62.72M | 59.77M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2008 | Mar 2009 | Apr 2010 | Apr 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Apr 2016 | Apr 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 764.30M | 833.26M | 911.13M | 1.46B | 1.51B | 1.49B | 1.32B | 1.24B | 1.24B | 1.27B | 1.27B | 1.82B | 1.86B | 1.93B | 2.20B | 2.45B | 2.40B |
| Total Equity | 494.19M | 539.88M | 593.12M | 686.14M | 732.63M | 769.18M | 837.89M | 826.12M | 721.57M | 739.61M | 752.43M | 667.87M | 587.11M | 731.67M | 749.42M | 818.00M | 959.96M | 820.84M | 796.32M |
| Cash & Equivalents | 133.55M | 156.72M | 141.56M | 196.71M | 228.86M | 179.12M | 192.47M | 160.66M | 115.12M | 139.56M | 180.17M | 169.35M | 137.31M | 192.31M | 259.50M | 284.47M | 178.80M | 306.76M | 245.44M |
| Long Term Debt | - | - | 4.46M | 3.97M | 2.88M | 456.94M | 392.06M | 406.37M | 364.53M | 253.62M | 59.42M | 322.45M | 305.51M | 690.59M | 559.44M | 754.10M | 797.56M | 921.23M | 1.22B |
| Current Liabilities | - | - | 135.05M | 108.67M | 130.74M | 180.14M | 216.93M | 188.68M | 185.55M | 211.18M | 384.70M | 235.76M | 274.82M | 253.50M | 442.27M | 251.82M | 300.38M | 578.11M | 282.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2009 | Apr 2010 | Apr 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Apr 2016 | Apr 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 116.36M | 130.67M | 123.45M | 115.32M | 85.07M | 139.52M | 127.18M | 121.86M | 159.74M | 220.35M | 159.28M | 158.22M | 108.81M | 172.26M | 273.06M | 181.75M | 181.72M | 293.22M |
| Investing Cash Flow | -60.00M | -132.34M | -51.56M | -52.20M | -596.39M | -105.83M | -121.77M | -104.77M | -73.31M | -63.04M | -116.15M | -57.18M | -425.44M | -86.34M | -143.79M | -322.39M | -161.90M | -179.55M |
| Financing Cash Flow | -30.74M | -13.97M | -18.08M | -30.47M | 461.85M | -20.70M | -33.16M | -62.62M | -60.41M | -120.64M | -50.63M | -131.21M | 367.45M | -15.75M | -100.36M | 38.16M | 108.82M | -178.46M |
| Capital Expenditure | -56.38M | -56.30M | -46.67M | -53.20M | -62.19M | -73.65M | -122.22M | -102.41M | -76.14M | -74.80M | -118.96M | -48.76M | -37.04M | -96.51M | -191.33M | -38.12M | -39.28M | -32.78M |
| Free Cash Flow | 59.98M | 74.36M | 76.79M | 62.12M | 22.89M | 65.88M | 4.96M | 19.46M | 83.60M | 145.55M | 40.32M | 109.46M | 71.77M | 75.75M | 81.73M | 143.63M | 142.45M | 260.44M |
| Share Buybacks | 60.00M | 40.00M | 50.00M | 50.00M | 50.00M | 0 | 39.03M | 60.98M | 0 | 100.00M | 160.00M | 175.00M | 0 | 0 | 75.00M | 0 | 225.00M | 175.00M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2009 | Apr 2010 | Apr 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Apr 2016 | Apr 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 51.5% | 52.3% | 52.5% | 50.7% | 48.0% | 49.9% | 47.7% | 44.7% | 42.7% | 45.6% | 43.2% | 49.0% | 45.7% | 50.9% | 52.6% | 52.8% | 55.0% | 59.0% |
| Operating Margin % | 14.3% | 12.9% | 16.3% | 12.2% | 6.3% | 4.9% | 4.5% | -4.8% | -2.2% | 6.2% | 8.6% | 10.5% | 10.3% | 8.1% | 13.4% | 12.6% | 16.3% | 11.7% |
| Net Margin % | 9.9% | 9.0% | 11.8% | 9.2% | 4.3% | 3.7% | 1.9% | -6.1% | -3.0% | 5.0% | 5.7% | 7.7% | 9.1% | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% |
| ROE % | 11.0% | 9.8% | 11.7% | 9.1% | 5.0% | 4.2% | 2.0% | -7.7% | -3.6% | 6.1% | 8.2% | 13.0% | 10.9% | 5.8% | 14.1% | 12.2% | 20.4% | 12.2% |
| ROCE % | - | 13.2% | 15.3% | 11.4% | 4.4% | 3.6% | 3.1% | -3.9% | -1.9% | 6.6% | 8.0% | 10.4% | 5.7% | 5.7% | 9.3% | 8.7% | 11.8% | 7.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.99% | 5.91M | $701.37M |
| 2 | Neuberger Berman Group, LLC | 9.19% | 4.18M | $496.06M |
| 3 | Vanguard Portfolio Management LLC | 5.60% | 2.55M | $302.23M |
| 4 | AQR Capital Management, LLC | 4.98% | 2.27M | $269.01M |
| 5 | Vanguard Capital Management LLC | 4.53% | 2.06M | $244.45M |
| 6 | Ariel Investments, LLC | 4.53% | 2.06M | $244.62M |
| 7 | State Street Corporation | 4.00% | 1.82M | $215.80M |
| 8 | Dimensional Fund Advisors LP | 3.48% | 1.59M | $188.15M |
| 9 | Citadel Advisors Llc | 3.32% | 1.51M | $179.24M |
| 10 | Geode Capital Management, LLC | 2.83% | 1.29M | $152.78M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HAE
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxORVRwVUp5MnA4eDRRd0FVY1JGSTV3NUZTa2Y1a2Z4amJsTmVQZGl6Z0RISkU3LW1nLVVIM3BPd2J1V2d3QTVtRG5GMDEyejQ2SlRlM0ZZZ3RXNTV1MmFZV0tiTGVkWTJDT01fOC12N2tyRTlVYXl5ZTUwVXRWenhaak9INUxkSEZqdGk0bH…
Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings? - TradingView
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOQWJXaTRuTGw0bmt3TXdrVExzdU10eTZLZTgyc0NZckNjeGlZZUt1LXNCRzlEZkViZGF4UGs5WDBPOVBKWjBJeTZMRmNkWXJWNXBVdFJmdHVRVXA3X25jZWlKSmtYODNIUjBlNTJGSE02OUJxRmRENU1xWG9abGRRLUw3eE5sTDg3NnNHaD…
Haemonetics Stock Price Forecast. Should You Buy HAE? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE5DRWxRV282aG8tUHdkaG1Ec0JyTVF2M3RaRFZUVHM2YTMybjZ6bm9JZTNxaVhKV0lEUThScWFiVU40blVBbTF3?oc=5" target="_blank">Haemonetics Stock Price Forecast. Should You Buy HAE?</a> <f…
A study found an artery-sealing device stopped bleeding in under a minute on average. FDA approved it. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNV1I5UjdyYU5UQVhzRG5EUndMWTljRVhERzlBcDBnSDlkRnNsTjdvUlAtMVc1cEFUUHJEQ3RlWG9oZ21UandPYXZDcVNDR0ZMZ3NvNXB2a0tsN1BOSG1mSUJ3cjFzR2dTU3dJWDlWQzlIVGNzZk5fVlRGQ1FLdlZ1YzhtYkRJcWVtMU03VV…
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNSXVydmZKWUY4SzR4VFNCbVMzVTJQYi00dG9sOFJ4M3VKOFVKZDdpWWVuQmFZREVKSTlzNGZiOFJYa2NtV29tYi1jMm9lMTFGSzVxWllSZmhGUGNTT2lWWDM2WE55aGhLNllub3Nsck1EblRvZXpxNFY4YjhQRHFCTmpJWEVpbmQ5MWZqYW…
Haemonetics rises after supply deal with CSL - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNNU1TOWV5enhyYno1WWNEMlBfcHFSZk5fTUxVMDZ0eW5iWE9MQkNrcWFXOWtWSmR4TWltdmwwS3JVbnJxOVlMWXdvVFhVdTdHNXJCTEVqNTZ2SlZrYmhnRzVxT1h3Q012a3pqNTFuX0E2MzZJaWtIZjFOLXpGVGZqX1RfWQ?oc=5" targe…
HAE — Frequently Asked Questions
What is the current share price of Haemonetics Corporation (HAE)?
As of 2026-10-22 16:30 PDT, Haemonetics Corporation (HAE) trades at $116.16 on NYSE. Its 52-week range is $47.67 to $122.06.
What is the market capitalisation of HAE?
Haemonetics Corporation (HAE) has a market capitalisation of $5.28B on NYSE.
What is the P/E ratio of HAE?
HAE trades at a trailing price-to-earnings (P/E) ratio of 56.12. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 5.89.
What is the return on equity (ROE) of HAE?
HAE has a return on equity (ROE) of 11.20%. Its return on capital employed (ROCE) is 7.42%.
Is HAE a good stock to buy?
This page provides a data-driven analysis of Haemonetics Corporation (HAE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.